4.8 Article

Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis

Journal

JOURNAL OF HEPATOLOGY
Volume 69, Issue 5, Pages 1037-1046

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2018.07.006

Keywords

Hepatic alveolar echinococcosis; Hepatic resection; Transplantation; Hepatectomy; Immunosuppression

Funding

  1. National Natural Science Foundation of China [U1303222]
  2. Xinjiang Uyghur Autonomous Region Key Scientific Research Program [201430123-2]
  3. National Key Laboratory on Causes and Prevention of Diseases with High Incidence in Central Asia [2010DS890294]

Ask authors/readers for more resources

Background & Aims: Radical resection is the best treatment for patients with advanced hepatic alveolar echinococcosis (AE). Liver transplantation is considered for selected advanced cases; however, a shortage of organ donors and the risk of postoperative recurrence are major challenges. The aim of this study was to assess the clinical outcomes of ex vivo liver resection and autotransplantation for end-stage AE. Methods: In this prospective study, 69 consecutive patients with end-stage hepatic AE were treated with ex vivo resection and liver autotransplantation between January 2010 and February 2017. The feasibility, safety and long-term clinical outcome of this technique were assessed. Results: Ex vivo extended hepatectomy with autotransplantation was successful in all patients without intraoperative mortality. The median weight of the graft and AE lesion were 850 (370-1,600) g and 1,650 (375-5,000) g, respectively. The median duration of the operation and anhepatic phase were 15.9 (8-24) h and 360 (104-879) min, respectively. Six patients did not need any blood transfusion. Complications higher than IIIa according to Clavien classification were observed in 10 patients. The 30-day-mortality and overall mortality (> 90 days) were 7.24% (5/69) and 11.5% (8/69), respectively. The mean hospital stay was 34.5 (12-128) days. Patients were followed-up systematically for a median of 22.5 months (14-89) without recurrence. Conclusion: This is the largest series assessing ex vivo liver resection and autotransplantation in end-stage hepatic AE. This technique could be an effective alternative to liver transplantation in patients with end-stage hepatic AE, with the advantage that it does not require an organ nor immunosuppressive agents. (C) 2018 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available